And Watertown

Abbott and Enanta Present Positive 12-Week Results and 3-Day Resistance Data From Phase 2 Study of ABT-450/r for Treatment of Hepatitis C

Older News

ABBOTT PARK, Illinois, and WATERTOWN, Massachusetts, April 4, 2011 - Abbott (NYSE: ABT) and Enanta Pharmaceuticals today announced 12-week results from a Phase 2 study of ABT-450/r, an investigational, oral protease inhibitor being developed for the treatment of hepatitis C (HCV) infection.

MORE..

Corporate
|
Products
|
About Me
|
Contact
|
Privacy Policy